Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.51 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | PPP5C | P53041 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.32 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16206588 | 1.00 | PDK1 (0.51) | PDK1MAP3K5MAP4K4HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL1119085 | 0.98 | PDK1 (0.50) | PDK1MAP3K5MAP4K4HTR2AHTR2C | |
| SCHEMBL13887630 | 0.83 | PDK1 (0.36) | PDK1MAP3K5MAP4K4ACKR3 | |
| SCHEMBL18909926 | 0.83 | PDK1 (0.36) | PDK1MAP3K5MAP4K4ACKR3 | |
| SCHEMBL16160608 | 0.82 | MAP4K4 (0.37) | PDK1MAP3K5MAP4K4SLC6A2CYP2D6 | |
| SCHEMBL1206257 | 0.82 | PDK1 (0.35) | PDK1MAP3K5MAP4K4 | |
| SCHEMBL1515598 | 0.82 | MAP4K4 (0.37) | PDK1MAP3K5MAP4K4SLC6A2CYP2D6 | |
| SCHEMBL27985446 | 0.82 | PDK1 (0.35) | PDK1MAP3K5MAP4K4 | |
| SCHEMBL16160601 | 0.82 | MAP4K4 (0.37) | PDK1MAP3K5MAP4K4SLC6A2CYP2D6 | |
| SCHEMBL24690484 | 0.79 | HRH3 (0.33) | PDK1MAP3K5SLC6A2CYP2D6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115261647-A | Morpholine carboxylic acid ionic liquid and method for extracting and separating samarium by using same | 成都理工大学 | 2022-11-01 | — | — | CN | claimed |
| EP-3083556-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2019-12-25 | — | — | EP | claimed |
| US-20080275064-A1 | Substituted Pyrimidines as Adenosine Receptor Antagonists | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | claimed |
| EP-1888565-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-02-20 | — | — | EP | claimed |
| WO-2006110884-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-10-19 | — | — | WO | claimed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2023235384-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-1029971-C | Process for preparating antiviral tetrahydroimidazo (1,4) benzodiazepines | JANSSEN PHARMACEUTICA NV (BE) | 1995-10-11 | — | — | CN | disclosed |
| CN-1076928-A | 1-[2-arylsulfonyl amino)-and the 1-oxoethyl] piperidine derivative and preparation and the application in treatment | SYNTHELABO (FR) | 1993-10-06 | — | — | CN | disclosed |
| EP-0226267-B1 | OXA-, THIA- AND DIAZABICYCLOALKANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BEECHAM GROUP PLC (GB) | 1993-01-13 | — | — | EP | disclosed |
| EP-0230179-B1 | 4-MORPHOLINYL 1H-INDOLE DERIVATIVES, THEIR SALTS, PROCESS AND INTERMEDIATES OF PREPARATION, USE AS THERAPEUTIC AGENTS, COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1992-09-30 | — | — | EP | disclosed |
| CN-1050192-A | Prepare the also method of [1,4] benzodiazepine of antiviral imidazolidine | JANSSEN PHARMACEUTICA NV (BE) | 1991-03-27 | — | — | CN | disclosed |
| US-4883874-A | Azabicyclic intermediates | BEECHAM GROUP PLC. OF BEECHAM HOUSE (GB) | 1989-11-28 | — | — | US | disclosed |
| US-4826839-A | GASTROINTESTINAL DISORDERS, HEADACHES | BEECHAM GROUP P.L.C. (GB) | 1989-05-02 | — | — | US | disclosed |
| EP-0230179-A2 | 4-Morpholinyl 1H-indole derivatives, their salts, process and intermediates of preparation, use as therapeutic agents, compositions containing them | ROUSSEL-UCLAF (FR) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | PDK1 430/4885MAP3K5 28/4885MAP4K4 57/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | PDK1 2926/4885MAP3K5 1295/4885MAP4K4 1041/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | PDK1 1969/4885MAP3K5 1602/4885MAP4K4 1728/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PDK1 2050/4885MAP3K5 4476/4885MAP4K4 4660/4885 |
| US-20080275064-A1 | Substituted Pyrimidines as Adenosine Receptor Antagonists | ADORA2A, ADORA3, ADORA1 | PDK1 1410/4885MAP3K5 3453/4885MAP4K4 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.